Inclusion Criteria:

- patients with histologically or cytologically diagnosed metastatic triple negative
breast cancer (Oestrogen, progesterone and HER2 negative adenocarcinoma of the
breast)

- Patients must have normal organ and bone marrow function, ECOG performance status of
no more than 2

- Formalin fixed, paraffin embedded tumour sample from the primary or recurrent cancer
must be available for central testing.

Exclusion Criteria:

- Any chemotherapy, radiotherapy (except for palliative reasons) or investigational
product, within 2 weeks from the last dose prior to study entry (or longer period,
depending on the agent used)

- Major surgery within 4 weeks of starting the study, and must have recovered from any
effects of major surgery

- Patients requiring treatment with the following:certain antibiotic drugs, St.John's
Wort, carbamazepine, phenobarbitone, phenytoin, and certain protease inhibitors/
non-nucleoside reverse transcriptase inhibitors used as components of HIV/AIDS
treatment,

- Patients with second primary cancer; except adequately treated non-melanoma skin
cancer, curatively treated in-situ cancer of the cervix, or other solid tumours
curatively treated with no evidence of disease for at least 5 years.